Fracture - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 48 pages report, published by Global Markets Direct

Keywords : Fracture Therapeutic Products under Development, Key Players in Fracture Therapeutics, Fracture Pipeline Overview, Fracture Pipeline, Fracture Pipeline Assessment

Report ThumbnailSeptember-2013
Fracture - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Fracture - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fracture, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fracture. Fracture - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fracture.
- A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fracture pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fracture.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fracture pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Fracture, H2 2013 7
  • Products under Development for Fracture - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Route of Administration, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Molecule Type, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 23
  • List of Tables
  • Number of Products Under Development for Fracture, H2 2013 7
  • Products under Development for Fracture - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Eli Lilly and Company, H2 2013 14
  • Kaken Pharmaceutical Co.,Ltd., H2 2013 15
  • KOLON LIFE SCIENCE INC., H2 2013 16
  • TissueGene, Inc., H2 2013 17
  • Radius Health, Inc., H2 2013 18
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 23
  • Fracture Therapeutics - Drug Profile Updates 34
  • Fracture Therapeutics - Discontinued Products 37
  • Fracture Therapeutics - Dormant Products 38
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Fracture Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Fracture 7
  • Fracture Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Fracture Therapeutics - Products under Development by Companies 13
  • Companies Involved in Fracture Therapeutics Development 14
  • Eli Lilly and Company 14
  • Kaken Pharmaceutical Co.,Ltd. 15
  • KOLON LIFE SCIENCE INC. 16
  • TissueGene, Inc. 17
  • Radius Health, Inc. 18
  • Fracture - Therapeutics Assessment 19
  • Assessment by Monotherapy Products 19
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Drug Profiles 24
  • teriparatide - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • KCB-1B - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • BA-058 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • KUR-113 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • KLS-Bfr - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • OsteoStem - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • TG-B - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Bone Morphogenetic Protein Modulators - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Fracture Therapeutics - Drug Profile Updates 34
  • Fracture Therapeutics - Discontinued Products 37
  • Fracture Therapeutics - Dormant Products 38
  • Fracture - Product Development Milestones 39
  • Featured News & Press Releases 39
  • Mar 11, 2013: Merck Provides Update On Fosamax Product Liability Trial 39
  • Feb 11, 2013: UCB And Amgen Decide Not To Pursue Phase III Clinical Trial Program For CDP7851 39
  • Jan 07, 2013: Radius Provides Update On Pivotal Phase III Program For BA058-SC Injection 40
  • Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR 40
  • Aug 07, 2012: Lilly Announces Study Results Regarding Postmenopausal Women With Back Pain Caused By Vertebral Fractures 41
  • Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111 43
  • Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures 43
  • Jun 01, 2010: Amgen Receives FDA Approval For Prolia For Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture 44
  • Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111 45
  • Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures 46
  • Appendix 47
  • Methodology 47
  • Coverage 47
  • Secondary Research 47
  • Primary Research 47
  • Expert Panel Validation 47
  • Contact Us 48
  • Disclaimer 48

Please select a license type

Share

Related Products

Global Markets DirectFracture - Pipeline Review, H2 2013Product ThumbnailFracture - Pipeline Review, H2 2013, Industry ReportProduct #: 113318
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved